Skip to main content
SpringerLink
Log in

Drug Therapy for Interstitial Lung Disease

  • Chapter
  • First Online:
Diffuse Lung Disease

  • 1533 Accesses

Abstract

This chapter summarizes the various potential medications used to treat interstitial lung diseases. The suggested administration routes and dosages are discussed. In addition, toxicity of the drugs and proposed monitoring for toxicity is presented. As newer agents become available, there is increasing information regarding the safety and efficacy of the new drugs as well as standard medications. In addition, individual drugs are used for an increasing number of interstitial lung diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis. 1990;142:1268–71.

    PubMed  CAS  Google Scholar 

  2. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270(5234):283–6.

    Article  PubMed  CAS  Google Scholar 

  3. Webster JC, Oakley RH, Jewell CM, et al. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA. 2001;98(12): 6865–70.

    Article  PubMed  CAS  Google Scholar 

  4. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med. 2008;29(3):533–48.

    Article  PubMed  Google Scholar 

  5. Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002; 19(3):198–204.

    PubMed  Google Scholar 

  6. Flaherty KR, Toews GB, Lynch III JP, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med. 2001;110(4):278–82.

    Article  PubMed  CAS  Google Scholar 

  7. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:60–6.

    PubMed  CAS  Google Scholar 

  8. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954–63.

    Article  PubMed  CAS  Google Scholar 

  9. Coulson KA, Reed G, Gilliam BE, et al. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009;15(4):155–60.

    Article  PubMed  Google Scholar 

  10. Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int. 1997; 61(5):382–5.

    Article  PubMed  CAS  Google Scholar 

  11. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–92.

    Article  PubMed  CAS  Google Scholar 

  12. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002; 4(4):266–73.

    Article  PubMed  Google Scholar 

  13. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax. 1999;54: 742–6.

    Article  PubMed  CAS  Google Scholar 

  14. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol. 1997;36(1):86–90.

    Article  PubMed  CAS  Google Scholar 

  15. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008; 359(26):2790–803.

    Article  PubMed  CAS  Google Scholar 

  16. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med. 1994;121:833–41.

    PubMed  CAS  Google Scholar 

  17. Kremer JM, Alarcon GS, Lightfoot Jr RW, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994; 37(3):316–28.

    Article  PubMed  CAS  Google Scholar 

  18. Roenigk HH, Auerbach R, Mailbach HI, et al. Methotrexate guidelines revised. J Am Acad Dermatol. 1982;6:145–55.

    Article  PubMed  Google Scholar 

  19. Baughman RP, Koehler A, Bejarano PA, et al. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch Intern Med. 2003;163(5):615–20.

    Article  PubMed  CAS  Google Scholar 

  20. Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med. 2002;8(5):470–6.

    Article  PubMed  Google Scholar 

  21. Zisman DA, McCune WJ, Tino G, et al. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18(3): 243–52.

    PubMed  CAS  Google Scholar 

  22. Schnabel A, Richter C, Bauerfeind S, et al. Bronchoalveolar lavage cell profile in methotrexate pneumonitis. Thorax. 1997;52:377–9.

    Article  PubMed  CAS  Google Scholar 

  23. Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis. 1997;14:121–30.

    CAS  Google Scholar 

  24. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:43–8.

    PubMed  Google Scholar 

  25. Rustin GJS, Rustin F, Dent J, et al. No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors. N Engl J Med. 1982;308:473–6.

    Article  Google Scholar 

  26. Balin PL, Tindall JP, Roenigk HH, et al. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis. JAMA. 1975;232:359–62.

    Article  Google Scholar 

  27. Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf. 2009;32(12):1123–34.

    Article  PubMed  CAS  Google Scholar 

  28. Chan V, Tett SE. How is leflunomide prescribed and used in Australia? Analysis of prescribing and adverse effect reporting. Pharmacoepidemiol Drug Saf. 2006;15(7):485–93.

    Article  PubMed  Google Scholar 

  29. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2000;39(6):655–65.

    Article  CAS  Google Scholar 

  30. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(9): 726–33.

    PubMed  CAS  Google Scholar 

  31. Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s ­granulomatosis. Rheumatology (Oxford). 2007;46(7): 1087–91.

    Article  CAS  Google Scholar 

  32. Savage RL, Highton J, Boyd IW, et al. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J. 2006; 36(3):162–9.

    Article  PubMed  CAS  Google Scholar 

  33. Martin K, Bentaberry F, Dumoulin C, et al. Peripheral neuropathy associated with leflunomide: is there a risk patient profile? Pharmacoepidemiol Drug Saf. 2007;16(1):74–8.

    Article  PubMed  CAS  Google Scholar 

  34. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis. 1991;144(2):291–6.

    Article  PubMed  CAS  Google Scholar 

  35. Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999; 14(5):1117–22.

    Article  PubMed  CAS  Google Scholar 

  36. Cooper SC, Ford LT, Berg JD, et al. Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. Pharmacogenomics. 2008;9(3):303–9.

    Article  PubMed  CAS  Google Scholar 

  37. Perri D, Cole DE, Friedman O, et al. Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase. Eur Respir J. 2007;30(5):1014–7.

    Article  PubMed  CAS  Google Scholar 

  38. Winter JW, Gaffney D, Shapiro D, et al. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2007;25(9):1069–77.

    Article  PubMed  CAS  Google Scholar 

  39. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28(8):973–83.

    Article  PubMed  CAS  Google Scholar 

  40. McKendry RJR, Cyr M. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a case-control study of 131 patients. Arch Intern Med. 1989;149:685–9.

    Article  PubMed  CAS  Google Scholar 

  41. Kehinde EO, Petermann A, Morgan JD, et al. Triple therapy and incidence of de nova cancer in renal transplants. Br J Surg. 1994;81:985–6.

    Article  PubMed  CAS  Google Scholar 

  42. Mackenzie KA, Wells JE, Lynn KL, et al. First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients. Nephrol Dial Transplant. 2010; 25(1):300–6.

    Article  PubMed  Google Scholar 

  43. Lebrun C, Debouverie M, Vermersch P, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler. 2008; 14(3):399–405.

    Article  PubMed  Google Scholar 

  44. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:b2480. doi:10.1136/bmj.b2480.:b2480.

    Article  PubMed  CAS  Google Scholar 

  45. Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999–2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6(11):1212–7.

    Article  PubMed  Google Scholar 

  46. Koukoura O, Mantas N, Linardakis H, et al. Successful term pregnancy in a patient with Wegener’s granulomatosis: case report and literature review. Fertil Steril. 2008;89(2):457.e1–5.

    Article  Google Scholar 

  47. Miniero R, Tardivo I, Curtoni ES, et al. Pregnancy after renal transplantation in Italian patients: focus on fetal outcome. J Nephrol. 2002;15(6):626–32.

    PubMed  Google Scholar 

  48. Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med. 1997;156(6):1897–901.

    PubMed  CAS  Google Scholar 

  49. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229–42.

    Article  PubMed  CAS  Google Scholar 

  50. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130(1):30–6.

    Article  PubMed  CAS  Google Scholar 

  51. van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17(3):871–80.

    Article  PubMed  CAS  Google Scholar 

  52. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86(8):1043–51.

    Article  PubMed  CAS  Google Scholar 

  53. Remuzzi G, Cravedi P, Costantini M, et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol. 2007;18(6):1973–85.

    Article  PubMed  CAS  Google Scholar 

  54. Wang K, Zhang H, Li Y, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc. 2004;36(7):2068–70.

    Article  PubMed  CAS  Google Scholar 

  55. Brewer JD, Colegio OR, Phillips PK, et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol. 2009;145(12):1391–6.

    Article  PubMed  Google Scholar 

  56. Fraile P, Garcia-Cosmes P, Martin P, et al. Non-skin solid tumors as a cause of morbidity and mortality after liver transplantation. Transplant Proc. 2009;41(6):2433–4.

    Article  PubMed  CAS  Google Scholar 

  57. Ostensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford). 2008;47 Suppl 3:iii28–31.

    Article  Google Scholar 

  58. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–66.

    Article  PubMed  CAS  Google Scholar 

  59. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962–70.

    Article  PubMed  CAS  Google Scholar 

  60. Corte TJ, Ellis R, Renzoni EA, et al. Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):132–8.

    PubMed  CAS  Google Scholar 

  61. Baughman RP, Lower EE. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest. 1992;102(4):1090–4.

    Article  PubMed  CAS  Google Scholar 

  62. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998;41(10):1835–44.

    Article  PubMed  CAS  Google Scholar 

  63. Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM. 1997;90(6):401–9.

    Article  PubMed  CAS  Google Scholar 

  64. Martin-Suarez I, D’Cruz D, Mansoor M, et al. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis. 1997;56(8): 481–7.

    Article  PubMed  CAS  Google Scholar 

  65. de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant. 2001;16(10):2018–27.

    Article  PubMed  Google Scholar 

  66. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124:477–84.

    PubMed  CAS  Google Scholar 

  67. Martin F, Lauwerys B, Lefebvre C, et al. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus. 1997;6(3):254–7.

    Article  PubMed  CAS  Google Scholar 

  68. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000;160(5):610–9.

    Article  PubMed  CAS  Google Scholar 

  69. Ramsey-Goldman R, Schilling E. Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am. 1997;23(1):149–67.

    Article  PubMed  CAS  Google Scholar 

  70. Lower EE, Blau R, Gazder P, et al. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med. 1999;8(7):949–54.

    Article  PubMed  CAS  Google Scholar 

  71. Elizur SE, Chian RC, Pineau CA, et al. Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. Rheumatology (Oxford). 2008;47(10):1506–9.

    Article  CAS  Google Scholar 

  72. Dorr FA, Coltman Jr CA. Second cancers following antineoplastic therapy. Curr Probl Cancer. 1985;9(2): 1–43.

    Article  PubMed  CAS  Google Scholar 

  73. Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160(1):192–7.

    PubMed  CAS  Google Scholar 

  74. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996;5 Suppl 1:S11–5.

    Article  PubMed  CAS  Google Scholar 

  75. Elder M, Rahman AM, McLay J. Early paracentral visual field loss in patients taking hydroxychloroquine. Arch Ophthalmol. 2006;124(12):1729–33.

    Article  PubMed  Google Scholar 

  76. Leecharoen S, Wangkaew S, Louthrenoo W. Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma. J Med Assoc Thai. 2007;90(1):52–8.

    PubMed  Google Scholar 

  77. Jones SK. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol. 1999;140: 3–7.

    Article  PubMed  CAS  Google Scholar 

  78. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10(6):401–4.

    Article  PubMed  CAS  Google Scholar 

  79. Motta M, Tincani A, Faden D, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol. 2005;25(2):86–9.

    Article  PubMed  CAS  Google Scholar 

  80. Renault F, Flores-Guevara R, Renaud C, et al. Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatr. 2009;98(9):1500–3.

    Article  PubMed  CAS  Google Scholar 

  81. Tavares JL, Wangoo A, Dilworth P, et al. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med. 1997;91(1):31–9.

    Article  PubMed  CAS  Google Scholar 

  82. Ye Q, Chen B, Tong Z, et al. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J. 2006;28(4):824–31.

    Article  PubMed  CAS  Google Scholar 

  83. Oliver SJ, Kikuchi T, Krueger JG, et al. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol. 2002;102(3):225–36.

    Article  PubMed  CAS  Google Scholar 

  84. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest. 2002;122:227–32.

    Article  PubMed  CAS  Google Scholar 

  85. Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol. 2004;50(2):235–41.

    Article  PubMed  Google Scholar 

  86. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol. 2003;1(3):194–205.

    PubMed  CAS  Google Scholar 

  87. Horton MR, Danoff SK, Lechtzin N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. Thorax. 2008;63(8):749.

    Article  PubMed  CAS  Google Scholar 

  88. Tilluckdharry L, Dean R, Farver C, et al. Thalidomide-related eosinophilic pneumonia: a case report and brief literature review. Cases J. 2008;1(1):143.

    Article  PubMed  Google Scholar 

  89. Buttin BM, Moore MJ. Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer. Gynecol Oncol. 2008;111(3):546–8.

    Article  PubMed  CAS  Google Scholar 

  90. Younis TH, Alam A, Paplham P, et al. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. Br J Haematol. 2003;121(1): 191–2.

    Article  PubMed  Google Scholar 

  91. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80(12):1568–74.

    Article  PubMed  CAS  Google Scholar 

  92. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006;33(12):2398–408.

    PubMed  CAS  Google Scholar 

  93. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802.

    Article  PubMed  CAS  Google Scholar 

  94. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177–85.

    Article  PubMed  CAS  Google Scholar 

  95. Baughman RP. Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Revista Portuguesa de Pneumonologia. 2007;13:S47–50.

    Google Scholar 

  96. Raghu G, Fatenejad S, McDermott L. Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J. 2006;28:767s.

    Google Scholar 

  97. Pham T, Claudepierre P, Deprez X, et al. Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Societe Francaise de Rhumatologie, SFR). Joint Bone Spine. 2005;72 Suppl 1:S1–58.

    PubMed  Google Scholar 

  98. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–84.

    Article  PubMed  CAS  Google Scholar 

  99. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987–1019.

    Article  PubMed  CAS  Google Scholar 

  100. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med. 2001;345:1098–104.

    Article  PubMed  CAS  Google Scholar 

  101. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261–5.

    Article  PubMed  CAS  Google Scholar 

  102. Gomez-Reino JJ, Carmona L, Angel DM. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57(5):756–61.

    Article  PubMed  CAS  Google Scholar 

  103. Matulis G, Juni P, Villiger PM, et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a mycobacterium tuberculosis antigen specific IFN-gamma assay. Ann Rheum Dis. 2008;67(1):84–90.

    Article  PubMed  CAS  Google Scholar 

  104. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522–8.

    Article  PubMed  CAS  Google Scholar 

  105. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006;21(9):1366–71.

    Article  PubMed  CAS  Google Scholar 

  106. Li S, Kaur PP, Chan V, et al. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol. 2009;28(7):787–91.

    Article  PubMed  CAS  Google Scholar 

  107. Huang W, Cordoro KM, Taylor SL, et al. To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. J Am Acad Dermatol. 2008;58(6):970–7.

    Article  PubMed  Google Scholar 

  108. Furst DE. The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis. Semin Arthritis Rheum. 2010;39(5):327–46.

    Article  PubMed  CAS  Google Scholar 

  109. Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61(3):305–12.

    Article  PubMed  CAS  Google Scholar 

  110. Tubach F, Ravaud P, Salmon-Ceron D, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis. 2006;43(10):e95–100.

    Article  PubMed  CAS  Google Scholar 

  111. Kapetanovic MC, Larsson L, Truedsson L, et al. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther. 2006;8(4):R131.

    Article  PubMed  CAS  Google Scholar 

  112. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242–51.

    Article  Google Scholar 

  113. Taki H, Kawagishi Y, Shinoda K, et al. Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol Int. 2009;30(2):275–6.

    Article  PubMed  Google Scholar 

  114. Daien CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883–6.

    Article  CAS  Google Scholar 

  115. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000;35(3):537–44.

    Article  PubMed  CAS  Google Scholar 

  116. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109(13):1594–602.

    Article  PubMed  CAS  Google Scholar 

  117. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133–40.

    Article  PubMed  CAS  Google Scholar 

  118. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002;86(2–3):123–30.

    Article  PubMed  Google Scholar 

  119. Rennard SI, Fogarty C, Kelsen S, et al. The Safety and Efficacy of Infliximab in Moderate-To-Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2007;175(9):926–34.

    Article  PubMed  CAS  Google Scholar 

  120. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005; 352(4):351–61.

    Article  Google Scholar 

  121. Hansen RA, Gartlehner G, Powell GE, et al. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5(6):729–35.

    Article  PubMed  Google Scholar 

  122. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56(5):1433–9.

    Article  PubMed  CAS  Google Scholar 

  123. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862–9.

    Article  PubMed  CAS  Google Scholar 

  124. Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65(3):379–84.

    Article  PubMed  CAS  Google Scholar 

  125. Lozeron P, Denier C, Lacroix C, et al. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol. 2009;66(4):490–7.

    Article  PubMed  Google Scholar 

  126. Katz JM, Bruno MK, Winterkorn JM, et al. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch Neurol. 2003;60(3):426–30.

    Article  PubMed  Google Scholar 

  127. Baughman RP, Bradley DA, Lower EE. Infliximab for chronic ocular inflammation. Int J Clin Pharmacol Ther. 2005;43:7–11.

    PubMed  CAS  Google Scholar 

  128. El Mourabet M, El Hashem S, Harrison JR, et al. Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review. Curr Drug Targets. 2010;11(2):234–41.

    Article  PubMed  Google Scholar 

  129. Berthelot JM, De Bandt M, Goupille P, et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine. 2009;76(1):28–34.

    Article  PubMed  CAS  Google Scholar 

  130. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 2009;36(3): 635–41.

    Article  PubMed  Google Scholar 

  131. Kane S, Ford J, Cohen R, et al. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn’s disease before and after delivery. J Clin Gastroenterol. 2009;43(7):613–6.

    Article  PubMed  CAS  Google Scholar 

  132. McLaughlin P. Rituximab: perspective on single agent experience, and future directions in combination trials. Crit Rev Oncol Hematol. 2001;40(1):3–16.

    Article  PubMed  CAS  Google Scholar 

  133. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006;173(2):180–7.

    Article  PubMed  CAS  Google Scholar 

  134. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64(6):913–20.

    Article  PubMed  CAS  Google Scholar 

  135. Leroux G, Costedoat-Chalumeau N, Brihaye B, et al. Treatment of relapsing polychondritis with rituximab: a retrospective study of nine patients. Arthritis Rheum. 2009;61(5):577–82.

    Article  PubMed  CAS  Google Scholar 

  136. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18(4):465–71.

    Article  PubMed  CAS  Google Scholar 

  137. Walewski J, Kraszewska E, Mioduszewska O, et al. Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. Med Oncol. 2001;18(2):141–8.

    Article  PubMed  CAS  Google Scholar 

  138. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999; 17(3):791–5.

    PubMed  CAS  Google Scholar 

  139. Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum. 2009;38(4):265–80.

    Article  PubMed  CAS  Google Scholar 

  140. Schwartzberg LS, Stepanski EJ, Fortner BV, et al. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer. 2008;16(4):393–8.

    Article  PubMed  Google Scholar 

  141. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31(6):456–73.

    Article  PubMed  CAS  Google Scholar 

  142. Sehn LH, Donaldson J, Filewich A, et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood. 2007;109(10):4171–3.

    Article  PubMed  CAS  Google Scholar 

  143. Tuthill M, Crook T, Corbet T, et al. Rapid infusion of rituximab over 60 min. Eur J Haematol. 2009;82(4): 322–5.

    Article  PubMed  CAS  Google Scholar 

  144. Aksoy S, Dizdar O, Hayran M, et al. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma. 2009;50(3): 357–65.

    Article  PubMed  CAS  Google Scholar 

  145. Burr ML, Malaviya AP, Gaston JH, et al. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology (Oxford). 2008;47(5):738–9.

    Article  CAS  Google Scholar 

  146. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48(7):1307–12.

    Article  PubMed  CAS  Google Scholar 

  147. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834–40.

    Article  PubMed  CAS  Google Scholar 

  148. Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum. 2009;60(11):3225–8.

    Article  PubMed  CAS  Google Scholar 

  149. Major EO, Amemiya K, Tornatore CS, et al. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 1992;5(1):49–73.

    PubMed  CAS  Google Scholar 

  150. Baldo P, Cecco S, Giacomin E, et al. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets. 2008;8(8):647–65.

    Article  PubMed  CAS  Google Scholar 

  151. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140–51.

    Article  PubMed  CAS  Google Scholar 

  152. Stenton SB, Partovi N, Ensom MH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet. 2005;44(8):769–86.

    Article  PubMed  CAS  Google Scholar 

  153. Rangan GK, Nguyen T, Mainra R, et al. Therapeutic role of sirolimus in non-transplant kidney disease. Pharmacol Ther. 2009;123(2):187–206.

    Article  PubMed  CAS  Google Scholar 

  154. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation. 2001;72(5):787–90.

    Article  PubMed  CAS  Google Scholar 

  155. Garrean S, Massad MG, Tshibaka M, et al. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant. 2005;19(5):698–703.

    Article  PubMed  Google Scholar 

  156. Khalife WI, Kogoj P, Kar B. Sirolimus-induced alveolar hemorrhage. J Heart Lung Transplant. 2007;26(6):652–7.

    Article  PubMed  Google Scholar 

  157. Nocera A, Andorno E, Tagliamacco A, et al. Sirolimus therapy in liver transplant patients: an initial experience at a single center. Transplant Proc. 2008;40(6):1950–2.

    Article  CAS  PubMed  Google Scholar 

  158. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;36(3):695–6.

    Article  Google Scholar 

  159. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1061–9.

    PubMed  CAS  Google Scholar 

  160. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040–7.

    Article  PubMed  Google Scholar 

  161. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.

    Article  PubMed  CAS  Google Scholar 

  162. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590(1–3):400–8.

    Article  PubMed  CAS  Google Scholar 

  163. Spond J, Case N, Chapman RW, et al. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm Pharmacol Ther. 2003;16(4):207–14.

    Article  PubMed  CAS  Google Scholar 

  164. Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22(4):279–85.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    Robert P. Baughman MD

  2. Department of Pneumology/Allergy, Ruhrlandklinik, University Hospital, Essen, Germany

    Ulrich Costabel MD

  3. Barnett Cancer Center, University of Cincinnati, Cincinnati, OH, USA

    Elyse E. Lower MD

Authors
  1. Robert P. Baughman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Costabel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elyse E. Lower MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert P. Baughman MD .

Editor information

Editors and Affiliations

  1. University of Cincinnati, College of Medicine, Department of Internal Medicine, Eden Ave, Cincinnati, 45267-0565, Ohio, USA

    Robert P. Baughman

  2. of Respiratory Medicine, Imperial College, Emeritus Professor, Grand Ave 14, London, N10 3BB, United Kingdom

    Roland M. du Bois

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Baughman, R.P., Costabel, U., Lower, E.E. (2012). Drug Therapy for Interstitial Lung Disease. In: Baughman, R., du Bois, R. (eds) Diffuse Lung Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9771-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9771-5_7

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-9770-8

  • Online ISBN: 978-1-4419-9771-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation